Eli Lilly is the dominant player in incretin obesity and diabetes care. Tirzepatide — Mounjaro for type-2 diabetes, Zepbound for obesity — generated the bulk of 2025 growth, and SURMOUNT-5, the first definitive Phase 3B head-to-head against semaglutide, read out 21.6% mean weight loss at 72 weeks versus semaglutide's 15.4%. Q1 2026 revenue reached $19.8 billion (+56% YoY) on Mounjaro $8.66B (+125%) and Zepbound $4.16B (+80%); Lilly raised 2026 guidance to $82–85B on April 30 and the stock climbed 6.11% on May 1. On May 4, an FAERS hepatic-failure case for Foundayo surfaced, sending shares down 3% premarket before recovering on Lilly's safety-data response and an RBC 'baseline noise' defense.
The next layer determines 2027 and beyond. Orforglipron, marketed as Foundayo, became the first small-molecule oral GLP-1 cleared for obesity in April 2026 and reached roughly 20,000 patients and more than 8,000 prescribers in its first three weeks, though Wegovy pill outpaced it ~20× in early-May IQVIA volume. Retatrutide, the GLP-1/GIP/glucagon triple agonist, posted its first Phase 3 type-2 diabetes readout (TRANSCEND T2D1: A1c down 1.7–2.0 pts, 25–37 lb mean weight loss) on the April 30 call alongside the prior TRIUMPH-4 obesity-with-knee-osteoarthritis data. Lilly's Phase 3 SYNERGY-Outcomes trial (NCT07165028) is testing retatrutide and tirzepatide against placebo on serious liver outcomes in about 4,500 people with MASLD. LillyDirect handles self-pay distribution. On September 24, 2026, the FDA approved Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin for adults with type 2 diabetes, after four Phase 3 QWINT trials showed A1C reduction non-inferior to daily insulin glargine or degludec.
The company has spent 2024 and 2025 building peptide CDMO capacity to support both branded volume and the long shadow of the compounding fight. June 2026 forced a manufacturing geography rethink: Lilly halved its planned €2.3 billion ($2.7B) Alzey, Rhineland-Palatinate injectable plant to roughly €1.15 billion and cut planned headcount from 1,000 to 500, citing Germany's proposed 'dynamic manufacturer rebate' and the broader healthcare-reform package. The redirected capital is heading to US sites, most likely Lilly's Pennsylvania facility, alongside the previously announced $4.5 billion Indiana 'Medicine Foundry' R&D and manufacturing project. Boehringer Ingelheim is making a parallel German cut. The Alzey scale-back arrived the same week as STAT News' June 23 disclosure that the FDA and Lilly granted compassionate-use retatrutide access to a 79-year-old patient on the application of NIH senior clinician Dr. Ranganath Muniyappa, with the White House publicly denying that President Trump applied. Stories here track the pipeline, deals, manufacturing geography, and the share-price moves that follow them.
At the Aging Research and Drug Discovery (ARDD) meeting at Harvard on October 1-3, 2026, Novo Nordisk researchers reported that in protein data from 10,052 participants in five semaglutide trials, the drug lowered an estimate of heart biological age by about 2 to 4 years at the first follow-up measurement, according to the meeting's poster abstracts. Longevity.Technology reported on October 4 that Novo also modeled SELECT trial results in a UK cohort of 19,117 people to project 1.9 life-years gained, and that a Lilly epigenetic substudy with 71 paired SURMOUNT-5 participants found all 15 epigenetic clocks showed less aging than the 1.38 years that had passed, two of them statistically significant. Lilly called its work preliminary and hypothesis-generating, with no placebo or control group, and biological-age clocks are not established clinical outcomes.
Lilly announced on Tuesday, September 29, 2026 an indirect treatment comparison, presented at EASD, of Zepbound (tirzepatide) 10 mg and 15 mg against Novo's Wegovy HD (semaglutide 7.2 mg), using its own SURMOUNT-1 trial and Novo's STEP UP trial in adults with obesity and without diabetes. At 72 weeks, under the treatment-regimen estimand, Zepbound 15 mg and 10 mg were estimated to give 4.5 and 3.2 percentage points more weight loss; under the efficacy estimand, the differences were 1.8 and 0.7 points and were not statistically significant. Lilly said discontinuation for adverse events was comparable; the analysis was Lilly-funded, and the two drugs have not been tested head to head at these doses.
Lilly presented the Phase 3 ACHIEVE-4 trial of its oral small-molecule GLP-1 drug Foundayo (orforglipron) at EASD on Thursday, October 1, 2026, alongside publication in The Lancet. In 2,749 adults with type 2 diabetes, overweight or obesity, and increased cardiovascular risk, Foundayo met its noninferiority goal against insulin glargine for cardiovascular death, heart attack, stroke, or hospitalization for unstable angina (MACE-4 hazard ratio 0.84; 95% CI 0.59 to 1.20); the three-part MACE-3 hazard ratio was 0.77 (95% CI 0.52 to 1.13). At 52 weeks, A1C fell 1.6 points versus 1.0 and weight fell 8.8% versus a 1.7% gain on glargine. Lilly also reported a lower rate of death from any cause (hazard ratio 0.43) but described that analysis as exploratory and not controlled for multiple comparisons; 10.6% of Foundayo patients stopped treatment because of adverse events.
CVS Caremark's addition of Lilly's Zepbound back to its commercial template formularies as an additional preferred weight-loss option takes effect on Thursday, October 1, 2026, the date the pharmacy benefit manager set when it announced the reversal on May 28. NBC News reported that about 25 million to 30 million people are covered under Caremark's standard formulary, which had excluded Zepbound in favor of Novo's Wegovy since 2025. Plan sponsors that use the templates can still customize coverage, so whether a given patient's plan covers Zepbound depends on the employer.
Lilly presented full results of TRIUMPH-2 at EASD on Wednesday, September 30, 2026, alongside publication in The Lancet: 1,152 adults with obesity or overweight and type 2 diabetes were randomized to weekly retatrutide 4, 9, or 12 mg or placebo for 80 weeks. Under the efficacy estimand, weight fell 12.7%, 19.1%, and 20.8% versus 4.0% with placebo, A1C fell 1.4, 1.6, and 1.5 points versus 0.2, 59.5% of people on 12 mg no longer met BMI criteria for obesity, and up to 40.0% reached an A1C below 5.7%. Discontinuation for adverse events was 3.8%, 11.6%, and 7.7% versus 4.9% on placebo, and dysesthesia, abnormal skin sensations, occurred in 4.5% to 7.3% of retatrutide patients versus 0.7%. Lilly plans to submit retatrutide to the FDA in the first quarter of 2027.
Lilly announced on Wednesday, September 30, 2026 Phase 2b results for EloraTZP, the amylin receptor agonist eloralintide given with tirzepatide as separate injections, in 367 adults with obesity or overweight and type 2 diabetes across 10 arms. At 48 weeks, under the efficacy estimand, eloralintide 9 mg plus tirzepatide 15 mg produced 23.3% weight loss versus 14.8% with tirzepatide 15 mg alone and 3.0% with placebo, and A1C fell 2.9 points versus 2.4 and 0.3 from a baseline near 8.1%. Discontinuation for adverse events was 10.8% to 27.0% with the combinations, 2.9% with tirzepatide alone, and 16.7% with placebo, and gastrointestinal events were more frequent on the combinations. Lilly plans to start Phase 3 trials of a co-formulated EloraTZP product by the end of 2026 with an adjusted dose-escalation schedule.
Lilly announced on Tuesday, September 29, 2026 an indirect treatment comparison, presented at EASD, of its oral small-molecule GLP-1 drug Foundayo (orforglipron) 17.2 mg against Novo's oral semaglutide 25 mg in adults with type 2 diabetes, using data from Lilly's ACHIEVE-3 trial and Novo's PIONEER PLUS trial. At 52 weeks, Foundayo was associated with 1.5 percentage points more weight loss (95% CI -2.7 to -0.2) and a 0.3-point larger A1C reduction (95% CI -0.6 to -0.1); sensitivity analyses gave 1.5 to 2.4 points and 0.3 to 0.6 points. Lilly's Rachel Batterham said head-to-head trials give the best comparison of two medicines, and the two drugs have not been tested directly against each other at these doses.
Eli Lilly announced on Thursday, September 24, 2026 that the FDA approved Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin used with diet and exercise to control blood sugar in adults with type 2 diabetes; it is not for type 1 diabetes because of an increased risk of severe hypoglycemia. Approval rests on four Phase 3 QWINT trials in more than 3,400 adults, in which efsitora met non-inferiority for A1C reduction against daily insulin glargine (QWINT-1, n=795; QWINT-4, n=730) and insulin degludec (QWINT-2, n=928; QWINT-3, n=986). Onswik will come in U-500 and U-1,000 prefilled pens delivering up to 400 and 800 units per injection, and Lilly expects U.S. availability in the coming months. It is already approved in the European Union, Mexico, and Japan.
A federal jury in the Northern District of California found on Thursday, September 24, 2026 that Eli Lilly breached the implied covenant of good faith and fair dealing in its license agreement with Nektar Therapeutics for rezpegaldesleukin (rezpeg), an autoimmune disease drug, and awarded Nektar $90 million in damages plus interest to be set by the court. Nektar filed the suit in August 2023, and the trial began on September 8. The verdict remains subject to post-trial proceedings, and any judgment may be appealed.
InnoCare Pharma announced on Thursday, September 24, 2026 a research collaboration and license agreement with Eli Lilly to discover medicines against up to five undisclosed targets in cancer and autoimmune disease. InnoCare can receive up to $100 million in upfront and near-term payments and up to about $3.25 billion in development and commercial milestones, plus single-digit tiered royalties on sales. InnoCare will use its own discovery platform to find and advance compounds; the announcement did not specify the type of drug.
The FDA approved Eli Lilly's Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) on Friday, September 18, 2026 for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer whose disease progressed after at least one line of endocrine therapy. The FDA also approved the Guardant360 CDx assay as the companion diagnostic for detecting ESR1 mutations. The approval rests on the EMBER-3 trial, which enrolled 874 adults; in the 159-patient ESR1-mutated subgroup, median progression-free survival was 11.1 months with the combination versus 5.5 months with imlunestrant alone (hazard ratio 0.53). Objective response rates were 35% and 15%, respectively.
The oral GLP-1 launch race entered its ninth month with Novo Nordisk's Wegovy pill (oral semaglutide 25 mg for chronic weight management, U.S. launch January 5, 2026) reaching approximately 183,000 weekly total scripts per the most recent IQVIA week ending September 5, 2026 — the highest weekly total since launch. Eli Lilly's Foundayo (orforglipron, once-daily oral small-molecule non-peptide GLP-1 receptor agonist, U.S. launch April 2026) continued its own prescription climb through the same reporting window. Both products are indicated for adults with obesity or overweight with weight-related comorbidities. Wegovy pill's climb reflects continued Medicare Part D coverage expansion following the November 2025 pricing agreement (Ozempic Pill / Wegovy pill at $149/month per the deal) and CMS 2026 formulary guidance. Foundayo pricing on TrumpRx and cash-pay LillyDirect anchors at $149/month at starting doses. The concurrent oral launch trajectories are the largest test to date of oral incretin adoption relative to the established weekly-injectable class dominated by injectable Wegovy and Zepbound.
Eli Lilly (NYSE: LLY) continued rollout through September 2026 of the early-access program for retatrutide (a once-weekly subcutaneous injectable GIP/GLP-1/glucagon triple agonist peptide for obesity) ahead of the Q1 2027 BLA submission plan confirmed after the July 23, 2026 TRIUMPH-2 and TRIUMPH-3 Phase 3 wins in obesity plus type 2 diabetes and obesity plus established cardiovascular disease. The 12 mg retatrutide dose produced 28.3% mean weight loss at 80 weeks in the TRIUMPH-1 Phase 3 obesity monotherapy trial reported in May 2026, the highest weight loss reported for any obesity therapy in a Phase 3 setting. TRIUMPH-4 (knee osteoarthritis, 68 weeks) added 28.7% weight loss plus improvements in pain and physical function. Seven Phase 3 readouts total are expected across the retatrutide program in 2026. Lilly management has framed retatrutide as the successor commercial franchise to Zepbound and Mounjaro, with launch anticipated 2027-2028 under the Most Favored Nation pricing framework that would apply from initial approval per the November 2025 pricing agreement.
The Trump administration's landmark November 6, 2025 GLP-1 drug pricing agreement with Eli Lilly and Novo Nordisk continues implementation through September 2026 with the TrumpRx.gov direct-to-consumer platform on schedule for January 2026 launch. Terms confirmed as of September 1, 2026: starting doses of Wegovy and Zepbound available at $350/month on TrumpRx (trending down to $245/month over a two-year period); Medicare prices set at $245/month for Ozempic, Wegovy, Mounjaro, and Zepbound, with Medicare beneficiaries paying $50/month copays; upcoming oral obesity pills (Lilly Foundayo, Novo Wegovy pill) priced at $149/month for Medicare, Medicaid, and TrumpRx patients. The Most-Favored-Nation pricing framework requires both companies to guarantee MFN prices on all new medications and repatriate increased foreign revenue on existing products. The agreement extends Medicare coverage to Wegovy and Zepbound for obesity plus related comorbidities for the first time, ending the Medicare Part D exclusion that has constrained the class since launch.
H1 2026 GLP-1 franchise reporting places Eli Lilly (NYSE: LLY) tirzepatide (Mounjaro plus Zepbound) at nearly $27.7 billion in first-half revenue, an 88% year-over-year increase, versus Novo Nordisk (NYSE: NVO) semaglutide (Ozempic plus Wegovy plus Rybelsus plus Wegovy pill) at approximately $17.5 billion. The revenue gap between the two GLP-1 leaders has widened from under $2 billion at the same point last year to $10.2 billion, driven by Zepbound share gains in U.S. obesity following SURMOUNT-5 superiority data over Wegovy, Mounjaro upside in international markets (China +93% CER, Rest of World +136%), Foundayo (orforglipron) first commercial quarter contribution of $98 million, and semaglutide patent expiries approaching in select markets (generic Ozempic expected in Canada). Novo has cut 12,000 positions in H1 2026 and lowered gross margin outlook to 78%, while Lilly raised full-year 2026 revenue guidance to $85-87 billion.
Follow-through analyst commentary Tuesday August 25, 2026 on the Monday Roche (SIX: ROG) and Hanmi Pharm HM17321 urocortin-2 (UCN2) obesity licensing deal positioned Roche as now targeting a top-three global obesity commercial position behind Eli Lilly (Zepbound, Mounjaro, Foundayo, and upcoming retatrutide) and Novo Nordisk (Wegovy, Ozempic, Wegovy Pill, Wegovy HD, CagriSema under review). Deal recap: $190 million upfront, up to $2.3 billion in milestones, plus tiered royalties; Genentech gets global rights excluding South Korea. HM17321 mechanism: a proprietary urocortin-2 (UCN2) analog peptide that selectively activates the corticotropin-releasing factor 2 receptor (CRFR2), a mechanism distinct from the incretin pathway (GLP-1, GIP) that anchors every currently-approved obesity drug. Roche obesity portfolio positioning: HM17321 combines with Roche's existing CT-388 (a dual GIP/GLP-1 receptor agonist acquired in the December 2023 Carmot Therapeutics acquisition for $2.7 billion, currently in Phase 2 for obesity and type 2 diabetes) and the emerging Roche obesity pipeline including RG7500 orforglipron precursor and other early-stage assets. The multi-mechanism portfolio provides a differentiated commercial positioning to compete across weight-loss efficacy (Roche's incretin agonist candidates match Lilly and Novo) and muscle-preservation (HM17321's differentiated UCN2 mechanism designed for lean mass preservation). Roche's obesity ambition contrasts with prior investor skepticism about its late-cycle entry into the category; Tuesday's analyst commentary suggests the multi-mechanism strategy could position Roche credibly for 2028-2030 commercial launches assuming pipeline programs advance to registration.
Eli Lilly (NYSE: LLY) clarified that the retatrutide (once-weekly injectable GIP/GLP-1/glucagon triple agonist peptide) regulatory submission timeline was pushed from end-2026 to Q1 2027 as the company continues gathering manufacturing and quality control data required for the FDA Biologics License Application. TRIUMPH-1 (obesity without type 2 diabetes) Phase 3 readout updated documented 28.3% mean weight loss at 80 weeks on the 12 mg weekly injection arm in 2,339 participants, second only to the 28.7% Lilly reported for TRIUMPH-4 among Phase 3 obesity trials. Combined with TRIUMPH-2 (obesity plus type 2 diabetes at up to 20.8% weight loss and 1.6 percentage point HbA1c reduction in 1,152 participants), TRIUMPH-3 (additional confirmatory data), and TRIUMPH-4 (obesity plus knee osteoarthritis at 28.7% weight loss and 75.8% WOMAC pain reduction), the retatrutide package now anchors four major indication frames. Additional TRIUMPH readouts expected across 2026 in obstructive sleep apnea, chronic lower back pain, and cardio-renal-metabolic outcomes will strengthen the label breadth. The Q1 2027 filing timeline shift is a modest delay from prior end-2026 signaling but reflects manufacturing-scale challenges typical of peptide APIs at the projected multi-billion-dollar commercial demand level (semaglutide and tirzepatide combined are already at roughly $80 billion annual revenue). Potential FDA approval expected in 2027 to 2028 following the standard 10-month review or 6-month priority review if a Priority Review Voucher (PRV) is deployed. Retatrutide will likely reshape the entire obesity drug class ceiling on the injectable side once approved.
Seoul Economic Daily published Monday August 17, 2026 a market synthesis on the obesity drug runner-up field. Key runners-up positioning for 2027-2028 approval filings behind Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO): Structure Therapeutics (NASDAQ: GPCR) with aleniglipron (once-daily oral small-molecule GLP-1 receptor agonist) expected to initiate Phase 3 in H2 2026; Amgen (NASDAQ: AMGN) with MariTide (once-monthly injectable dual GIPR antagonist / GLP-1 agonist) now positioned as the sole obesity focus after the July 29 Q2 disclosure that Amgen halted AMG 513 Phase 1 development to concentrate resources on the MariTide MARITIME Phase 3 program; and Pfizer (NYSE: PFE) with danuglipron oral GLP-1 receptor agonist plus the Metsera acquisition pipeline. Amgen expects to apply for MariTide regulatory approval in late 2026 to early 2027. The Amgen MariTide Phase 3 program covers obesity (MARITIME-1) plus obesity and type 2 diabetes (MARITIME-2), with additional Phase 3 studies exploring cardiovascular disease, heart failure, kidney disease, and obstructive sleep apnea. The sorting of winners from losers based on Phase 3 results will begin in earnest starting next year as the field competes on efficacy, safety, delivery format, and price for market share behind Lilly's Zepbound-Mounjaro-Foundayo franchise and Novo's Wegovy-Ozempic franchise.